AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24843528
Drug: glibenclamide 1.25-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glibenclamide 1.25-2.5 mg/day
Trial: 24843582
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg ginsam
Trial: 24843582
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg ginsam
Trial: 24843582
Drug: 3000 mg
RxNorm normalized name: talc 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 mg ginsam
Trial: 24843631
Drug: Exenatide twice-daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide twice-daily (EBID)
Trial: 24843697
Drug: Atorvastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin therapy (10, 20, and 40 mg)
Trial: 24843710
Drug: Insulin regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin regimen change
Trial: 24843716
Drug: Empagliflozin 1
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 1 mg
Trial: 24843782
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and Pioglitazone (comparison)
Trial: 24846037
Drug: Genotype-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-directed therapy
Trial: 24846037
Drug: Any oncogenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any oncogenic driver(s) without genotype-directed therapy
Trial: 24846037
Drug: Matched targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched targeted therapy or trial
Trial: 24846496
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 110 mg oral dose
Trial: 24848086
Drug: Automated, repetitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated, repetitive filling of 100 mL warm saline starting with an empty bladder
Trial: 24848086
Drug: Automated, repetitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated, repetitive filling of 100 mL warm saline starting with a low prefilled bladder volume (100 mL)
Trial: 24848086
Drug: Automated, repetitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated, repetitive filling of 100 mL warm saline starting with a high prefilled bladder volume (persistent desire to void)
Trial: 24848086
Drug: Automated, repetitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated, repetitive filling of 100 mL cold saline starting with an empty bladder
Trial: 24849582
Drug: Amuvatinib (100-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amuvatinib (100-800 mg/day every 21 days)
Trial: 24852920
Drug: SR Fampridine
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SR Fampridine 10 mg BID for 4 weeks
Trial: 24853169
Drug: Benznidazole 5-8
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole 5-8 mg/kg/day BID for 60 days
Trial: 24853169
Drug: Benznidazole treatment
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole treatment in children under 7 years
Trial: 24855165
Drug: Optimized insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimized insulin injection technique
Trial: 24855165
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin injection technique
Trial: 24857248
Drug: Antiplatelet/anticoagulation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet/anticoagulation therapy
Trial: 24857280
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline nasal irrigation (twice daily for 8 weeks)
Trial: 24857280
Drug: Intranasal corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal corticosteroid alone
Trial: 24857345
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day, escalated by 50 mg every 2 weeks to a maximum of 300 mg/day)
Trial: 24859366
Drug: SL-401 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SL-401 at 12.5 μg/kg intravenously over 15 minutes daily for up to 5 doses
Trial: 24859907
Drug: Panobacumab (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobacumab (three doses of 1.2 mg/kg)
Trial: 24862830
Drug: Metformin; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin; specific dosage and duration not mentioned
Trial: 24867540
Drug: Neoadjuvant short-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant short-course proton-based radiation with capecitabine (5 daily doses of 5 GyE)
Trial: 24867717
Drug: Natrelle round
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natrelle round silicone implants (augmentation)
Trial: 24867717
Drug: Natrelle round
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natrelle round silicone implants (revision-augmentation)
Trial: 24867717
Drug: Natrelle round
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natrelle round silicone implants (reconstruction)
Trial: 24867717
Drug: Submuscular placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submuscular placement of implants (augmentation)
Trial: 24867717
Drug: Overall implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall implants (magnetic resonance imaging cohort)
Trial: 24867717
Drug: Augmentation subjects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation subjects
Trial: 24867717
Drug: Revision-augmentation subjects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revision-augmentation subjects
Trial: 24868099
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg per day until disease progression or intolerable adverse events
Trial: 24872229
Drug: Subcutaneous interleukin
RxNorm normalized name: interleukin-11
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous interleukin 2 (1.5 million IU/d for 5 days, followed by three 5-day courses of 3 million IU/d at weeks 3, 6, and 9)
Trial: 24872229
Drug: Subcutaneous interleukin
RxNorm normalized name: interleukin-11
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous interleukin 2
Trial: 24872402
Drug: Tirasemtiv 375
RxNorm normalized name: Tirasemtiv
DrugBank: Tirasemtiv (DB12209)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirasemtiv 375 mg
Trial: 24872402
Drug: Tirasemtiv 750
RxNorm normalized name: Tirasemtiv
DrugBank: Tirasemtiv (DB12209)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirasemtiv 750 mg
Trial: 24872402
Drug: Tirasemtiv 500
RxNorm normalized name: Tirasemtiv
DrugBank: Tirasemtiv (DB12209)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirasemtiv 500 mg (after dose adjustment)
Trial: 24872728
Drug: Early follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early follow-up by telephone consultations (4 and 14 days post-discharge) in addition to conventional treatment
Trial: 24872728
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment following discharge from hospital
Trial: 24875132
Drug: AZD8931 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 monotherapy (40/60/80 mg bid for 21 days)
Trial: 24875132
Drug: AZD8931 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 40 mg bid plus paclitaxel 90 mg/m² (days 1, 8, 15 of 28-day cycle)
Trial: 24875132
Drug: AZD8931 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 monotherapy and combination therapy
Trial: 24876243
Drug: Community interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community interventions (e.g., preparedness bracelets and stroke warning magnets)
Trial: 24878054
Drug: Congenital adrenal
RxNorm normalized name: adrenal cortex extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Congenital adrenal hyperplasia (CAH) treatment
Trial: 24878054
Drug: Glucocorticoid only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid only treatment in women
Trial: 24879333
Drug: Alisertib ECT
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib ECT (50 mg BID for 7 days)
Trial: 24879333
Drug: Alisertib ECT
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib ECT (doses ≥ 40 mg BID)
Trial: 24879786
Drug: Previous 23-valent
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous 23-valent polysaccharide vaccine (PPSV23)
Trial: 24879844
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hsTnT and NT-proBNP
Trial: 24880136
Drug: Probiotic (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (Lactobacillus salivarius PS2) administered for 21 days
Trial: 24881994
Drug: Hypertension (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertension (blood pressure ≥140/90 mm Hg or those receiving blood pressure-lowering drugs)
Trial: 24882673
Drug: Enzalutamide 160mg
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160mg orally daily
Trial: 24883065
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of baseline FGF21 levels with dynamic changes in glucose and insulin levels during OGTT
Trial: 24884512
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA supplementation (5 g/d of fish oil supplement containing 1.9-2.2 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid) for 6 weeks
Trial: 24884694
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment of cardiovascular risk factors over 3 months, maintained for 2 years.
Trial: 24884782
Drug: Conventional glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucocorticoid replacement therapy
Trial: 24885258
Drug: HER2-targeted therapies
RxNorm normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HER2-targeted therapies
Trial: 24885755
Drug: IOERT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IOERT with a median dose of 15 Gy, median electron energy of 6 MeV, median cone size of 9 cm
Trial: 24885755
Drug: Postoperative EBRT
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative EBRT with a median dose of 46 Gy after IOERT or 60 Gy without IOERT
Trial: 24885755
Drug: Multimodal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal therapy including IOERT and postoperative EBRT
Trial: 24886078
Drug: Sugar absorption
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar absorption test in FD patients
Trial: 24886078
Drug: Sugar absorption
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar absorption test in controls
Trial: 24886192
Drug: Dietary ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary ascorbic acid intake (100 mg/day higher)
Trial: 24886512
Drug: Everolimus treatment
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus treatment with positive expression of phospho-mTOR
Trial: 24886512
Drug: Everolimus treatment
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus treatment with positive expression of phospho-S6RP
Trial: 24886512
Drug: Everolimus treatment
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus treatment with negative expression of phospho-4EBP1 and phospho-AKT
Trial: 24888813
Drug: GAA peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAA peptide vaccination with EphA2, IL-13Rα2, and survivin peptides emulsified in Montanide-ISA-51, administered subcutaneously every 3 weeks for eight courses, followed by booster vaccinations every 6 weeks.
Trial: 24889179
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) at 250 mg/day for 24 weeks
Trial: 24890385
Drug: TGF-β antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TGF-β antagonists
Trial: 24890858
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m² IV on d1, 4, 8, 11) and Doxorubicin (15 mg/m² IV on d1, 8) in 21-day cycles
Trial: 24891274
Drug: Decitabine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (15 mg/m2 iv) and Vorinostat (230 mg/m2 PO div BID) followed by chemotherapy (vincristine, prednisone, PEG-asparaginase, doxorubicin)
Trial: 24891429
Drug: Mefloquine/artesunate (fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine/artesunate (fixed-dose combination) administered orally once daily for 3 days
Trial: 24892263
Drug: Etanercept (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (0.4 mg/kg, maximum 25 mg/dose) twice weekly for 4 to 8 weeks
Trial: 24892263
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (control)
Trial: 24892422
Drug: Gammaplex (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gammaplex (5% Intravenous Immunoglobulin, IVIg) at a dosage of 1 g/kg on two consecutive days
Trial: 24892422
Drug: Gammaplex (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gammaplex (5% Intravenous Immunoglobulin, IVIg)
Trial: 24894084
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDCT) with two cycles of Epirubicin and Paclitaxel (Epi-Tax), followed by three consecutive HDCT cycles (one with Paclitaxel/Thiotepa (Thio-Tax) and two with Ifosfamide-Carboplatin-Etoposide regimen)
Trial: 24895163
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PESP presence and LVEF ≤ 35%
Trial: 24898091
Drug: Ultra-low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low dose (ULD) IL-2
Trial: 24898305
Drug: Ombrabulin (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombrabulin (35 mg/m(2), 30-min infusion, day 1 every 3 weeks) with cisplatin (75 mg/m(2), day 1) and docetaxel (75 mg/m(2), day 2)
Trial: 24898305
Drug: Ombrabulin (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombrabulin (35 mg/m(2), 30-min infusion, day 1 every 3 weeks) with carboplatin (AUC6) and paclitaxel (200 mg/m(2), day 2)
Trial: 24898305
Drug: Ombrabulin (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombrabulin (35 mg/m(2))
Trial: 24898305
Drug: Cisplatin/docetaxel or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/docetaxel or carboplatin/paclitaxel (standard doses)
Trial: 24898549
Drug: RG7155 (anti-CSF-1R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7155 (anti-CSF-1R antibody)
Trial: 24900938
Drug: Daily interruption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interruption of continuous sedative and opioid infusion
Trial: 24901360
Drug: Neoadjuvant gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant gemcitabine 1000 mg/m intravenously over 100 minutes and oxaliplatin 80 mg/m intravenously over 2 hours, every 2 weeks.
Trial: 24901360
Drug: Adjuvant gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant gemcitabine 1000 mg/m intravenously over 30 minutes days 1, 8, and 15 every 4 weeks.
Trial: 24902119
Drug: Ulcerogenic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulcerogenic medication
Trial: 24903189
Drug: Imipenem 750
RxNorm normalized name: CILASTATIN NA 750MG/IMIPENEM 750MG/VIL INJ IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem 750 mg every 6 hours
Trial: 24903189
Drug: Imipenem 1000
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem 1000 mg every 8 hours
Trial: 24903189
Drug: Imipenem 1000
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem 1000 mg every 6 hours
Trial: 24903629
Drug: Lestaurtinib 80
RxNorm normalized name: Lestaurtinib
DrugBank: Lestaurtinib (DB06469)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lestaurtinib 80 mg twice daily for 18 weeks
Trial: 24903795
Drug: Intermittent regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent regimen of rifampin (RMP), pyrazinamide (PZA), and ethambutol (EMB) administered BIW or TIW for 6 months after initial daily doses.
Trial: 24904120
Drug: Oral ixazomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ixazomib at maximum tolerated dose (MTD) of 2.97 mg/m(2) given weekly for 3 of 4 weeks.
Trial: 24904120
Drug: Oral ixazomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ixazomib at MTD of 2.97 mg/m(2).
Trial: 24905490
Drug: Pegylated-interferon/ribavirin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated-interferon/ribavirin therapy
Trial: 24905490
Drug: IL28B rs12979860
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL28B rs12979860 CC SNP
Trial: 24905490
Drug: ApoH and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApoH and IL28B CC SNP
Trial: 24906637
Drug: Canakinumab (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (initial dose 150 mg or 300 mg, escalating up to 600 mg every 4 weeks)
Trial: 24906637
Drug: Canakinumab (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (at maximum dose)
Trial: 24907635
Drug: Tremelimumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (15 mg/kg) plus gemcitabine (1000 mg/m² on days 1, 8, and 15 of each 28-day cycle)
Trial: 24907635
Drug: Tremelimumab (6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (6, 10, or 15 mg/kg) plus gemcitabine
Trial: 24912489
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg PO daily) and Everolimus (10 mg PO daily)
Trial: 24912660
Drug: Intestinal uptake
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intestinal uptake of p-cresol (measured by 24 h urinary excretion of PCS)
Trial: 24912660
Drug: Higher urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher urinary excretion of PCS (per 100 μmol increase)
Trial: 24912660
Drug: Urinary excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary excretion of PCS (in multivariate analysis)
Trial: 24913040
Drug: 10-item survey
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-item survey administered to patients
Trial: 24913066
Drug: Vandetanib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib (300 mg daily for a maximum of 10 weeks)
Trial: 24913999
Drug: Antiplatelet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet and anticoagulant therapy strategies
Trial: 24914044
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day (cohort 1)
Trial: 24914044
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day (cohort 2)
Trial: 24914044
Drug: Lenalidomide 15
RxNorm normalized name: lenalidomide 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 15 mg/day plus Sunitinib 37.5 mg/day (cohort 3)
Trial: 24914044
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day (MTD)
Trial: 24914044
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day
Trial: 24914120
Drug: Voriconazole and
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole and anidulafungin combination therapy
Trial: 24914120
Drug: Anidulafungin treatment
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anidulafungin treatment duration